Project description
Finding a new purpose for old drugs
Bringing new treatments to patients does not only involve new drug discovery. The repurposing of already existing and marketed drugs to treat both common and rare diseases is another viable proposition. The EU-funded DRUGtrain project will develop a paradigm for multidisciplinary research, ideal for improving drug repurposing and development strategies of compounds with autosomal dominant polycystic kidney disease, for example. Specifically, the project will use innovative bioinformatics and cheminformatics approaches to identify potential drug targets and drug candidates for repurposing. It will also perform drug testing/screening in advanced in vitro and in vivo models, ultimately leading to testing of new treatment strategies. DRUGtrain is also developing network activities to boost collaboration between academia, industry and patient organisations.
Objective
Drug repurposing (or repositioning) is the application of previously identified drugs or compounds to treat new indications.
The International Rare Diseases Research Consortium (IRDiRC) set as main goal for 2027 that 1000 new therapies for rare
diseases will be approved. One of the levers to achieve this goal includes the repurposing of already existing and marketed
drugs. In this context, DRUGtrain offers a timely paradigm for multidisciplinary research ideal for improving drug repurposing
and development strategies of compounds, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) as example.
Identifying compounds for repurposing requires a broad variety of approaches. Therefore, the aim of DRUGtrain is to offer a
multidisciplinary research training program to young researchers preparing them to become leading scientists able to
integrate molecular and pharmacological data, and translate fundamental research questions to the (pre)clinic and vice
versa.
The research objectives of DRUGtrain are: 1) To identify potential drug targets and drug candidates for repurposing using
innovative bio-informatics and cheminformatics approaches; 2) To perform drug testing/drug screenings in advanced in vitro
and in vivo models, ultimately leading to testing of new treatment strategies; 3) To clarify drug mechanisms, and identify and
reduce adverse events using state-of-the-art technologies from in silico and wet lab methodologies. Complementary training
through courses will cover additional topics in drug repurposing and drug discovery as well as scientific skills, personal
development, commerce and entrepreneurship.
In DRUGtrain, 6 academic and 4 private sector beneficiaries/partner organisations and 1 NGO are collaborating in joining
forces to intensify network activities between academia, industry, and a patient organization. The training offered should
support the ESRs in becoming the next generation of true multidisciplinary researchers in (bio)pharmaceutical sciences.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- social sciences political sciences political policies civil society civil society organisations nongovernmental organizations
- social sciences economics and business business and management entrepreneurship
- social sciences economics and business business and management commerce
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-ITN-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2333 ZA Leiden
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.